We are live on ! Find out more
ANTX icon

AN2 Therapeutics
ANTX

52 hedge funds and large institutions have $74.8M invested in AN2 Therapeutics in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

657% more capital invested

Capital invested by funds: $9.88M → $74.8M (+$64.9M)

178% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 9

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

41% more funds holding

Funds holding: 37 → 52 (+15)

29.3% more ownership

Funds ownership: 31.62% → 60.92% (+29%)

Holders
52
Holders Change
+15
Holders Change %
+40.54%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
13
Reduced
8
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$6.51M
2
CC
Commodore Capital
New York
+$4.82M
3
Millennium Management
Millennium Management
New York
+$4.39M
4
SSC
Spruce Street Capital
New York
+$3.43M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.06M

Top Sellers

Rank Fund Capital Flow
1
PLC
Peapod Lane Capital
New York
-$1.1M
2
P
Pfizer
New York
-$815K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$334K
4
Renaissance Technologies
Renaissance Technologies
New York
-$289K
5
LCM
Landscape Capital Management
New Jersey
-$276K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$10.8M +$6.51M +3,153,640 New
CC
2
Commodore Capital
New York
$7.98M +$4.82M +2,333,713 New
Millennium Management
3
Millennium Management
New York
$7.6M +$4.39M +2,126,819 +2,223%
SSC
4
Spruce Street Capital
New York
$5.58M +$3.43M +1,661,073 New
AC
5
Almitas Capital
California
$5.06M – – –
VCM
6
Vanguard Capital Management
Pennsylvania
$3.46M +$2.09M +1,011,078 New
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$3.42M +$2.06M +1,000,000 New
WP
8
Woodline Partners
California
$3.4M +$1.75M +847,700 +581%
BCM
9
Boxer Capital Management
California
$2.56M +$1.55M +749,035 New
SCM
10
Stonepine Capital Management
Oregon
$2.44M +$178K +86,177 +14%
Ameriprise
11
Ameriprise
Minnesota
$2.38M +$1.44M +696,181 New
SCM
12
Sio Capital Management
New York
$2.25M +$1.36M +657,200 New
ABG
13
Ally Bridge Group
New York
$1.8M +$1.09M +526,315 New
PM
14
Prosight Management
Texas
$1.76M +$1.06M +515,754 New
Bank of Nova Scotia
15
Bank of Nova Scotia
Ontario, Canada
$1.57M – – –
Bank of America
16
Bank of America
North Carolina
$1.35M +$17.3K +8,390 +2%
BlackRock
17
BlackRock
New York
$1.09M -$9.43K -4,567 -1%
Jane Street
18
Jane Street
New York
$1.04M +$590K +285,714 +1,593%
LCM
19
Landscape Capital Management
New Jersey
$1.02M -$276K -133,594 -31%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$981K +$71.6K +34,672 +14%
Bank of Montreal
21
Bank of Montreal
Ontario, Canada
$890K -$334K -161,950 -38%
Morgan Stanley
22
Morgan Stanley
New York
$801K +$9.12K +4,417 +2%
CF
23
Cantor Fitzgerald
New York
$684K +$413K +200,000 New
SFCM
24
Seven Fleet Capital Management
California
$683K +$412K +199,701 New
Renaissance Technologies
25
Renaissance Technologies
New York
$680K -$289K -139,800 -41%
1
2 3

ANTX Hedge Fund Activity: Q1 2026 in Review

52 of the 8,129 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q1 2026, worth a combined $74.8M — up 657% from $9.88M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ANTX positions and 9 closed out — a net gain of 16 holders — while 13 added to existing stakes and 8 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $6.51M. The largest seller was Peapod Lane Capital, cutting an estimated $1.1M.

  • 52 institutional investors held AN2 Therapeutics (ANTX) as of Q1 2026, up from 37 in Q4 2025.
  • Funds reported $74.8M of AN2 Therapeutics stock for Q1 2026, up 657% quarter-over-quarter.
  • 25 funds opened new AN2 Therapeutics positions in Q1 2026 and 9 closed out, a net change of +16 holders.
  • The largest AN2 Therapeutics buyer in Q1 2026 was Vivo Capital, an estimated $6.51M added.
  • The largest AN2 Therapeutics seller in Q1 2026 was Peapod Lane Capital, an estimated $1.1M sold.

Based on aggregated 13F filings for Q1 2026.